The stock of BioNTech SE ADR (BNTX) has gone down by -5.00% for the week, with a 34.33% rise in the past month and a 40.40% rise in the past quarter. The volatility ratio for the week is 4.62%, and the volatility levels for the past 30 days are 5.50% for BNTX. The simple moving average for the last 20 days is 16.94% for BNTX’s stock, with a simple moving average of 27.00% for the last 200 days.
Is It Worth Investing in BioNTech SE ADR (NASDAQ: BNTX) Right Now?
Company’s 36-month beta value is 0.22.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 3 as “overweight,” 9 as “hold,” and 2 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNTX is 237.11M, and currently, short sellers hold a 1.09% ratio of that floaft. The average trading volume of BNTX on September 25, 2024 was 945.21K shares.
BNTX) stock’s latest price update
BioNTech SE ADR (NASDAQ: BNTX)’s stock price has soared by 4.79 in relation to previous closing price of 113.05. Nevertheless, the company has seen a loss of -5.00% in its stock price over the last five trading days. zacks.com reported 2024-09-23 that The Committee for Medicinal Products for Human Use recommends marketing authorization for Pfizer and BioNTech’s updated version of mRNA COVID-19 jab, Comirnaty.
Analysts’ Opinion of BNTX
Jefferies, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $150, previously predicting the price at $96. The rating they have provided for BNTX stocks is “Buy” according to the report published on September 17th, 2024.
JP Morgan gave a rating of “Neutral” to BNTX, setting the target price at $125 in the report published on September 16th of the current year.
BNTX Trading at 29.75% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -9.90% of loss for the given period.
Volatility was left at 5.50%, however, over the last 30 days, the volatility rate increased by 4.62%, as shares surge +35.38% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +40.62% upper at present.
During the last 5 trading sessions, BNTX fell by -5.00%, which changed the moving average for the period of 200-days by +16.90% in comparison to the 20-day moving average, which settled at $102.86. In addition, BioNTech SE ADR saw 12.25% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTX starting from ATHOS KG, who proposed sale 55,605 shares at the price of $124.71 back on Sep 18 ’24. After this action, ATHOS KG now owns shares of BioNTech SE ADR, valued at $6,934,500 using the latest closing price.
ATHOS KG, the 10% Owner of BioNTech SE ADR, proposed sale 30,162 shares at $124.49 during a trade that took place back on Sep 17 ’24, which means that ATHOS KG is holding shares at $3,754,792 based on the most recent closing price.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.23 for the present operating margin
- 0.64 for the gross margin
The net margin for BioNTech SE ADR stands at -0.19. The total capital return value is set at -0.03. Equity return is now at value -2.58, with -2.26 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 11.73. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -18.57.
Currently, EBITDA for the company is 1.16 billion with net debt to EBITDA at 46.33. When we switch over and look at the enterprise to sales, we see a ratio of 5.59. The receivables turnover for the company is 9.39for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.54.
Conclusion
In a nutshell, BioNTech SE ADR (BNTX) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
